Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Ripretinib

INSIGHT

Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 54

NCT05734105

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Ripretinib 150 mg2L GIST, ctDNA KIT exon 11 + 17/18, no exon 9/13/14150 mgITTsunitinib 50 mg 4/2n/r
Sunitinib 50 mg 4/22L GIST, ctDNA KIT exon 11 + 17/1850 mgITTn/rn/r

No efficacy figure is in this file for this study.